



Population pharmacokinetics and pharmacodynamics of mycophenolic acid using the prospective data in patients undergoing hematopoietic stem cell transplantation

Yoshimura, Kazuaki ; Yano, Ikuko ; Yamamoto, Takashi ; Kawanishi, Misaki ; Isomoto, Yui ; Yonezawa, Atsushi ; Kondo, Tadakazu ; Takaori-...

(Citation)

Bone Marrow Transplantation, 53(1):44-51

(Issue Date)

2018-01

(Resource Type)

journal article

(Version)

Accepted Manuscript

(Rights)

© 2017, Springer Nature

(URL)

<https://hdl.handle.net/20.500.14094/90004835>



Population pharmacokinetics and pharmacodynamics of mycophenolic acid using prospective data in patients undergoing hematopoietic stem cell transplantation

Kazuaki Yoshimura^{1,2}, Ikuko Yano^{1,2,3}, Takashi Yamamoto², Misaki Kawanishi^{1,2}, Yui Isomoto², Atsushi Yonezawa^{1,2}, Tadakazu Kondo⁴, Akifumi Takaori-Kondo⁴, and Kazuo Matsubara²

¹Department of Clinical Pharmacy and Education, Graduate School of Pharmaceutical Science, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan.

²Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Sakyo-ku, Kyoto 606-8507, Japan.

³Department of Pharmacy, Kobe University Hospital, Chuo-ku, Kobe 650-0017, Japan.

⁴Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto 606-8507, Japan

Running heading:

Population analysis of mycophenolic acid

17

18 **Conflict of interest:** The authors declare no conflict of interest.

19

20 This study was supported in part by JSPS KAKENHI Grant Number JP25460210.

21

22 **Corresponding Author:** Ikuko Yano, PhD

23 Department of Pharmacy, Kobe University Hospital,

24 Chuo-ku, Kobe 650-0017, Japan

25 Tel.: +81-78-382-6641

26 Fax: +81-78-382-6676

27 E-mail Address: iyano@med.kobe-u.ac.jp

28

29

30

Abstract

Mycophenolate mofetil (MMF), a prodrug of mycophenolic acid (MPA), is used to suppress *graft-versus-host* disease in patients undergoing hematopoietic stem cell transplantation (HCT). The purpose of this study was to construct a population pharmacokinetic and pharmacodynamic model in HCT patients for individualized MPA therapy. Blood samples were obtained from 49 HCT patients after starting MMF therapy. Population pharmacokinetic and pharmacodynamic parameters were obtained using the program NONMEM. MPA was described via a 1-compartment model with a first order elimination, and 30.9% of MPA glucuronide (MPAG) was found in the enterohepatic circulation. Inosine-5'-monophosphate dehydrogenase (IMPDH) activity was modeled as a maximal inhibitory model with a half-maximal inhibitory concentration (IC_{50}) of 3.59 $\mu\text{g/mL}$ against MPA concentrations. Simulations based on the obtained pharmacokinetic and pharmacodynamic parameters revealed that decreased creatinine clearance increases the MPAG concentration followed by an increased MPA concentration; therefore, IMPDH activity decreases. Diarrhea decreases the enterohepatic circulation of MPAG and consequently reduces MPA concentration. The IC_{50} for MPA exhibited a positive association with C-reactive protein. Dosage adjustment based on plasma MPA concentration is required especially for patients with renal dysfunction and/or diarrhea.

47 **Introduction**

48 Mycophenolate mofetil (MMF) is clinically used to suppress *graft-versus-host* disease (GVHD) in
49 patients undergoing hematopoietic stem cell transplantation (HCT) and acute rejection after solid organ
50 transplantation^{1,2}. Mycophenolic acid (MPA), an active form of MMF, is metabolized by
51 glucuronosyltransferases in the liver. MPA glucuronide (MPAG) and MPA acyl glucuronide (AcMPAG)
52 are primarily produced by UGT1A9 and 2B7, respectively ³. While MPAG is an inactive metabolite,
53 AcMPAG exhibits pharmacological activity *in vitro* and is potentially responsible for the toxicity of MPA
54 ⁴. The majority of MPA metabolites are eliminated via the urine and partial elimination also occurs in the
55 bile mediated by multidrug resistance associated protein 2 (MRP2) followed by the entero-hepatic
56 recirculation ⁵.

57 The pharmacokinetics (PK) of MPA exhibits a large inter- and intra-individual variability, and it is
58 recommended that the area under the concentration-time curve (AUC) of MPA be monitored for
59 individualized therapy in solid organ transplant recipients^{6,7}. Recently, Arai et al. ⁸ proposed that MPA
60 drug monitoring was necessary for the effective prophylaxis of acute GVHD undergoing cord blood stem
61 cell transplantation (CBT). However, information regarding the optimal dose of MMF or the target range
62 for MPA concentrations in HCT patients is limited ⁹.

MPA selectively inhibits inosine-5'-monophosphate dehydrogenase (IMPDH) and suppresses the proliferation of B and T lymphocytes¹⁰. IMPDH exists as two isoforms derived from different genes^{11, 12}, and recombinant proteins of IMPDH2 is 4.8-fold more sensitive to MPA than IMPDH1¹³. The area under the effect curve (AUEC) of IMPDH activity on day 21 after HCT was reportedly associated with both non-relapse and overall mortality¹⁴. Therefore, the measurement of IMPDH activity in peripheral blood mononuclear cells (PBMCs) in addition to monitoring the AUC of MPA is considered to be an effective predictor of the clinical outcome of MPA therapy.

The PK of MPA is influenced by serum albumin, renal dysfunction, total bilirubin, age, co-administration with cyclosporine, and dose¹⁵⁻¹⁹. In addition, the incidence of acute rejection in the first year post-transplantation was significantly lower in carriers of SNPs for *IMPDH1* -106 G>A and 125 G>A compared with the respective wild-type individuals²⁰. The SNP for *IMPDH2* 3757 T>C was associated with a significantly higher IMPDH activity following the MMF intake, despite of no difference in the MPA exposure between groups²¹. The SNP for *MRP2* -24C>T was associated with a significantly higher dose-corrected MPA trough levels at later time points after transplantation²². The SNP for *UGT2B7* -842G>A resulted in a significantly higher AUC of AcMPAG at 1 and 3 months post-transplantation in patients with renal transplantation²³.

In this study, the effects of the patient characteristics including previously proven genetic polymorphisms were examined using a population PK and pharmacodynamics (PD) analysis. Effects of covariates were quantitatively evaluated by the simulation to examine the clinical significance of these covariates.

Subjects and Methods

Study design

A total of 49 adult Japanese HCT patients between March 2013 and August 2016 were included in the study. Acute GVHD prophylaxis comprised tacrolimus (PrografTM, Astellas Pharma Inc., Tokyo, Japan) and MMF (CellceptTM, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan) in CBT, plus short-term methotrexate (MethotrexateTM, Pfizer Japan Inc., Tokyo, Japan) in bone marrow transplant (BMT) or peripheral blood stem cell transplantation (PBT). MMF was orally administered at 10 mg/kg every 8 h (30 mg/kg/day), and was initiated on day -1 after CBT or on day 7 after BMT and PBT, except in one patient administered 15 mg/kg every 12 h. No potentially interacting drugs including cyclosporine or foods with MPA were co-administered.

Pre-transplant recipient DNA was used to determine *UGT2B7* -842C>T (rs7439366) and *MRP2* -24C>T (rs717620) genotypes. Approximately five weeks after MMF administration commenced,

post-transplant donor DNA as well as pre-transplant recipient DNA were used to determine *IMPDH1* 106G>A (rs2278294), *IMPDH1* 125G>A (rs2278293), and *IMPDH2* 3757T>C (rs11706052) genotypes. Blood samples were collected immediately before, 1, 2, 4, and 8 h after the first and third weeks after MMF administration commenced, plus blood sampling at 12 h after MMF administration in one patient administered 15 mg/kg every 12 h. This clinical study was approved by the Ethics Committee of Kyoto University Graduate School and Faculty of Medicine and Kyoto University Hospital. Written informed consent was obtained from all patients included in the study.

Analytical methods

Total plasma concentrations of MPA, MPAG, and AcMPAG were analyzed using LC-MS/MS according to the previously reported method²⁴. The lower limits of quantification (LLOQ) were 0.05, 0.2, and 0.02 µg/mL for MPA, MPAG, and AcMPAG, respectively. PBMC samples were used to measure the IMPDH activity according to the previous method²⁴. The IMPDH activity was calculated based on the XMP produced, which was normalized to the intracellular AMP. The LLOQ were 50 nM for both XMP and AMP. The data for AMP under the LLOQ were excluded from the analysis due to extremely low white blood cell counts after the transplantation.

Population PK/PD analysis

A population PK analysis was conducted using NONMEM. The overview of the basic PK/PD model for MPA is shown in Fig. 1. Since only the oral data were available, the relative bioavailability (F) of MPA was assumed to be 1. The model was parameterized using clearances for MPA, MPAG, and AcMPAG (CL_{MPA} , CL_{MPAG} , and CL_{AcMPAG}), as well as the volume of distribution for MPA, MPAG, and AcMPAG (V_{MPA} , V_{MPAG} , and V_{AcMPAG}). It was assumed that MPA was metabolized to MPAG and AcMPAG by a first-order process, in which 99 % and 1 % of MPA was converted to MPAG and AcMPAG, respectively, because the ratio of AUC_{0-8} for MPAG to AcMPAG was approximately 99:1 in this study. The enterohepatic circulation (EHC) was tested as a first-order process (K_{EHC}) from the central compartment of each metabolite to the gastrointestinal tract. For the comparison, 2-compartment model with EHC, and the lag time and the transit compartment models in the absorption process were tested²⁵. Additionally, EHC modeling by presuming a hypothetical gall bladder compartment was tested^{26, 27}.

Interindividual and interoccasion variability (IIV and IOV) in the PK/PD parameters were modeled using an exponential error model²⁸. The estimation for the IOV was as follows: occasions 1 and 2 pertained to one and three weeks after MMF administration commenced, respectively. The influence of each covariate on the population mean parameters was evaluated by the stepwise forward inclusion and backward elimination method, and significance levels were 1 % and 0.1 % (6.63 and 10.8 with freedom

of 1 assuming a chi-square distribution), respectively. The tested covariates for the PK parameters included body weight, gender, stem cell source, age, aspartate aminotransferase, serum albumin, total bilirubin, creatinine clearance (CL_{CR}), dose of MMF, diarrhea, and investigated genotypes for MRP2 and UGT2B7 of recipient. Diarrhea was defined as the occurrence of loose, muddy or watery stool, or more than five times per a day of fecal frequency in case of not recording the fecal condition.

Continuous variables were normalized by each population median using the following power function model:

$$\theta_i = \theta_{pop} \times \left(\frac{COV_i}{COV_{med}} \right)^{\theta_{cov}}$$

(1)

where θ_i is the individual model-predicted PK parameter (e.g. CL_{MPA}) for an individual with covariate value of COV_i . θ_{pop} represents the population mean for the parameter θ , COV_{med} represents the population median of the covariate, and θ_{cov} represents the covariate effect. For dichotomous variables, the value of COV_i is typically set to 0 for the normal classification and 1 for the other classifications in each individual as follows:

$$\theta_i = \theta_{pop} \times \theta_{cov}^{COV_i} \quad (2)$$

After the final population PK model was obtained, the relationship between the MPA concentrations and IMPDH activity was explored graphically and modeled using a direct sigmoid inhibitory maximum effect model as followed:

$$E = E_0 \times \left(1 - \frac{C_{MPA}^\gamma}{IC_{50,MPA}^\gamma + C_{MPA}^\gamma}\right) \quad (3)$$

where E_0 , $IC_{50,MPA}$, and γ represent baseline of IMPDH activity, half-maximal inhibitory MPA concentration, and the Hill coefficient to be estimated ²⁹, and C_{MPA} represents the MPA concentration. To investigate the effect of the AcMPAG concentration on IMPDH activity, an additional inhibitory effect model was tested ³⁰. The tested covariates for the PD parameters included the stem cell source, reduced-intensity conditioning, gender, age, serum albumin, C-reactive protein (CRP), and investigated genotypes (*IMPDH1* and 2) of donor or recipient. In the value of CRP was under the LLOQ (<0.2 mg/mL), this value was converted to 0.1 due to the difficulty of the calculation. Goodness-of-fit and prediction-corrected visual predictive check plots were used for internal validation ³¹. For prediction-corrected visual predictive check plots, the final PK/PD model was used to simulate original data sets at 1000 times compared with the observed data.

Simulation study

The effects of statistically significant covariates on the PK/PD of MPA were evaluated by the simulation using the final population parameters. The dose was fixed to 500 mg every 8 h for all simulations. In the simulation for the effect of each covariate, other covariates were fixed to the median value of each covariate and without diarrhea. The AUC_{0-8} or $AUEC_{0-8}$ were calculated using the linear trapezoidal method.

Results

Patient characteristics

The patient characteristics and the distribution of each genotype before and five weeks after the transplantation are summarized in Table 1. All of the observed genotype distributions were consistent with Hardy-Weinberg equilibrium.

Population PK modeling

In total, 522 concentration data for MPA, MPAG, and AcMPAG, respectively, were analyzed. Five samples with MPA concentrations under the LLOQ were replaced with half of the LLOQ³², and included in the analysis. 2-compartment model improved the model fitting compared with 1-compartment model

without EHC. However, after an inclusion of EHC process, 2-compartment model did not improve the model fitting compared with 1-compartment model ($\Delta\text{OBJ} = -8.12$), and a terminal elimination rate constant was not correctly estimated. Therefore, the PK of MPA was finally described by 1-compartment model with first order absorption and elimination, and was affected by the EHC of MPAG. An inclusion of the absorption lag-time did not improve the model fitting. Transit compartment model was not adopted owing to the high computational intensity required, although the model fit was significantly improved. Although the inclusion of EHC of AcMPAG in the model brought a statistically significant model improvement, $\text{CL}_{\text{AcMPAG}}$ was not correctly estimated. Therefore, the model including the EHC of only MPAG was selected. EHC modeling by presuming a hypothetical gall bladder compartment did not improve the model fitting compared with first-order EHC model. The simultaneous inclusion of IOVs for K_a , F , K_{EHC} , CL_{MPAG} , and $\text{CL}_{\text{AcMPAG}}$ significantly improved the model fitting ($\Delta\text{OBJ} = -721$). The final PK parameters and its relative standard error (RSE) are presented in Table 2. Figure 2 shows the inter-occasional parameters for one and three weeks after MMF administration commenced.

After the evaluation of each covariate, the serum albumin revealed a significant negative association with CL_{MPA} and V_{MPA} . CL_{CR} exhibited a significant positive relationship with both CL_{MPAG} and $\text{CL}_{\text{AcMPAG}}$, and K_{EHC} in the patients showing diarrhea was 0.375-fold lower than that without diarrhea (Table 2). An

inclusion of IIV was tested for all the MPA PK parameters and an exclusion of IIV was tested after inclusion of IOV. After all, IIVs on V_{MPA} and F were retained in the final model, and shrinkage values of them were 27.6% and 16.8%, respectively. The ratio for the EHC of MPAG was estimated to be 30.9% ($EHC (\%) = K_{EHC} / (K_{EHC} + CL_{MPAG} / V_{MPAG}) \times 100$) in patients with CL_{CR} of 112 mL/min without diarrhea.

PD modeling

A total of 460 IMPDH activity data from 49 patients were used for the PD model building following the PK modeling process. The 62 IMPDH activity data were excluded due to AMP under the LLOQ. The IMPDH activity was described with the inhibitory E_{max} model using the MPA concentrations. The Hill coefficient was fixed to 1 by the statistical selection ($\Delta OBJ = -3.00$). The additive inhibitory effect model for AcMPAG did not significantly improve the model fitting. An inclusion of IOV on E_0 significantly improved the model fitting ($\Delta OBJ = -200$). The value of IC_{50} for MPA revealed a positive association with CRP ($\Delta OBJ = -11.4$). No polymorphisms were identified as significant covariates in the PK/PD model. The final PD parameters with RSE are shown in Table 2. The IIV for IC_{50} was 81.2%, and its shrinkage was 29.7%. The goodness-of-fit and prediction-corrected visual predictive check

demonstrated that the population PK/PD model accurately predicted the observed MPA and its metabolites concentrations, as well as IMPDH activity (Figs. 3 and 4).

Simulation study

A total of 1,000 data sets in each group were simulated under the several renal functions with or without diarrhea (Fig. 5). The AUC_{0-8} of MPAG and AcMPAG significantly increased according to the decreased CL_{CR} compared with those for 120 mL/min. The AUC_{0-8} of MPA also significantly increased according to the decreased CL_{CR} . The $AUEC_{0-8}$ of IMPDH significantly decreased from 339 to 215 $\mu\text{mol}\cdot\text{h}\cdot\text{sec}^{-1}\cdot\text{mol AMP}^{-1}$ with a decrease in CL_{CR} from 120 to 10 mL/min; however, a large interindividual variability was noted. In addition, the diarrhea significantly decreased the AUC_{0-8} of both MPA and AcMPAG in every CL_{CR} , but did not affect the AUC_{0-8} of MPAG. The $AUEC_{0-8}$ of IMPDH with diarrhea was significantly higher than that without diarrhea in the case of CL_{CR} under 60 mL/min.

The AUC_{0-8} of MPA significantly decreased with a reduction in serum albumin, although the $AUEC_{0-8}$ of IMPDH did not significantly change (Fig. 6). At a MPA concentration of 3.59 $\mu\text{g/mL}$, which is equal to the population mean of IC_{50} in the case of CRP of 1.2 mg/dL, the IMPDH activity is 1.34-fold

higher in patients with CRP of 10 mg/dL, compared with that for CRP of 1.2 mg/dL. The AUEC₀₋₈ of IMPDH also significantly increases as the CRP rises.

Discussion

Patients undergoing HCT generally have intestinal mucosal damage due to a myeloablative or reduced intensity conditioning regimen prior to HCT³³. Indeed, MPA concentrations in HCT patients are generally lower than those of organ transplant patients despite an equivalent dose of MMF³⁴. In addition, leukopenia and co-administered antibiotics induce the destruction of intestinal flora, leading to diarrhea. The diarrhea decreased the reabsorption of MPA in the gastro-intestinal tract, and consequently decreased the MPA concentration. In this study, IMPDH activity in CL_{CR} under 60 mL/min with diarrhea was significantly higher compared to those in the same CL_{CR} without diarrhea in the same MPA dosing, secondary to the PK changes.

In the early phase after transplantation, HCT patients suffer from renal impairment due to thrombotic microangiopathy, which is an adverse effect caused by calcineurin inhibitors and high-dose chemotherapy³⁵. Since MPA metabolites are excreted into the urine, the clearance of MPA metabolites have been reported to decrease in association with lower renal function^{14, 36}. In the simulation using the

final PK/PD parameters, MPA concentration will be increased with a decreased CL_{CR} , due to the enhanced EHC of MPAG. Moreover, the IMPDH activity in CL_{CR} under 30 mL/min was significantly lower than that in 120 mL/min. Therefore, particular attention regarding extra-immunosuppression in response to MPA is needed for patients with severe renal dysfunction.

The target range of MPA exposure may be influenced by changes in serum albumin, since the free fraction of MPA was 1–2%³⁷. In the PD analysis, we speculated that the serum albumin had a significant effect on the IC_{50} value of MPA due to the changed unbound fraction of MPA; however, we were unable to conclusively demonstrate this effect due to a large inter- and intra-individual variability in IMPDH activity. Therefore, changes in the serum albumin in clinical situations might not have a significant effect on IMPDH activity, although it can affect the PK of MPA.

Interestingly, CRP exhibited a positive association with the IC_{50} for MPA. Patients undergoing HCT suffered from various symptoms caused by an infection and/or the excessive production of inflammatory cytokines on the days around the engraftment^{38, 39}. Indeed, the median of CRP in one week after starting the MMF therapy (3.0 mg/dL) was significantly higher than that in three weeks after the therapy (0.8 mg/dL). Moreover, IMPDH1 is constitutively expressed in normal leukocytes, whereas IMPDH2 is up-regulated in neoplastic and replicating cells^{40, 41}. These findings suggest the reasons why CRP

exhibited a positive association with the IC_{50} for MPA. Whether the elevated CRP value reflects infection or excessive production of inflammatory cytokines remains to be examined.

The simultaneous inclusion of IIVs and IOVs for PK/PD parameters significantly improved the model fitting. HCT patients have single or multiple damages due to the conditioning regimen, infection or excessive production of inflammatory cytokines^{33, 38, 39, 42}. In addition, the recovery rate of organic and hematopoietic functions following HCT showed a large variability. Therefore, the IIV and IOV in the PK/PD of MPA in HCT patients should be large.

The present study included some limitations. The PK of MPA is usually expressed as 2-compartment model, and/or sometimes includes more sophisticated models^{26, 27}. In this study, the model fitting was not improved by using any sophisticated models. The examined model largely depends on the experimental design, and we would like to pick up clinical significant covariates on the PK of MPA in a routine clinical care as shown in the previous our study⁸. Additionally, although our population size was modest, the estimated parameters, such as the ratio of EHC of MPAG or the IC_{50} for MPA, were similar to those of previous reports¹⁴. Therefore, the constructed PK/PD model for MPA was considered to be appropriate. The effects of covariates extracted in the present study should be examined by 2-compartment model using more rich sampling data in a future.

In conclusion, we successfully constructed a population PK/PD model of MPA in patients undergoing HCT. Renal dysfunction, diarrhea, and CRP are clinically significant factors affecting the PD of MPA in the same dosing regimen. Dosage adjustment based on plasma MPA concentration is required especially for patients with renal dysfunction and/or diarrhea.

Acknowledgments: The authors would like to thank Ms. Machiko Kaneyoshi for her assistant with blood sampling.

References

1. Kaufman DB, Shapiro R, Lucey MR, Cherikh WS, Bustami RT, Dyke DB. Immunosuppression: practice and trends. *Am J Transplant* 2004; **4**: 38-53.
2. Minagawa K, Yamamori M, Katayama Y, Matsui T. Mycophenolate mofetil: fully utilizing its benefits for GvHD prophylaxis. *Int J Hematol* 2012; **96**: 10-25.
3. Dupuis R, Yuen A, Innocenti F. The influence of UGT polymorphisms as biomarkers in solid organ transplantation. *Clinica Chimica Acta* 2012; **413**: 1318-1325.

- 286 4. Wieland E, Shipkova M, Schellhaas U, Schutz E, Niedmann PD, Armstrong VW *et al.* Induction
287 of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects? *Clin*
288 *Biochem* 2000; **33**: 107-113.
- 289 5. Patel CG, Ogasawara K, Akhlaghi F. Mycophenolic acid glucuronide is transported by
290 multidrug resistance-associated protein 2 and this transport is not inhibited by cyclosporine,
291 tacrolimus or sirolimus. *Xenobiotica* 2013; **43**: 229-235.
- 292 6. van Gelder T, Hilbrands LB, Vanrenterghem Y, Weimar W, de Fijter JW, Squifflet JP *et al.* A
293 randomized double-blind, multicenter plasma concentration controlled study of the safety and
294 efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney
295 transplantation. *Transplantation* 1999; **68**: 261-266.
- 296 7. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid
297 organ transplant recipients. *Clin Pharmacokinet* 2007; **46**: 13-58.
- 298 8. Arai Y, Kondo T, Kitano T, Hishizawa M, Yamashita K, Kadowaki N *et al.* Monitoring
299 mycophenolate mofetil is necessary for the effective prophylaxis of acute GVHD after cord
300 blood transplantation. *Bone Marrow Transplant* 2015; **50**: 312-314.

301 9. Wakahashi K, Yamamori M, Minagawa K, Ishii S, Nishikawa S, Shimoyama M *et al.*
302 Pharmacokinetics-based optimal dose prediction of donor source-dependent response to
303 mycophenolate mofetil in unrelated hematopoietic cell transplantation. *Int J Hematol* 2011; **94**:
304 193-202.

305 10. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action.
306 *Immunopharmacology* 2000; **47**: 85-118.

307 11. Collart FR, Huberman E. Cloning and sequence-analysis of the human and chinese-hamster
308 inosine-5'-monophosphate dehydrogenase cdnas. *J Biol Chem* 1988; **263**: 15769-15772.

309 12. Natsumeda Y, Ohno S, Kawasaki H, Konno Y, Weber G, Suzuki K. Two distinct cDNAs for
310 human IMP dehydrogenase. *J Biol Chem* 1990; **265**: 5292-5295.

311 13. Carr SF, Papp E, Wu JC, Natsumeda Y. Characterization of human type-I and Type-II IMP
312 dehydrogenases. *J Biol Chem* 1993; **268**: 27286-27290.

313 14. Li H, Mager DE, Sandmaier BM, Storer BE, Boeckh MJ, Bemer MJ *et al.* Pharmacokinetic and
314 pharmacodynamic analysis of inosine monophosphate dehydrogenase activity in hematopoietic
315 cell transplantation recipients treated with mycophenolate mofetil. *Biol Blood Marrow*
316 *Transplant* 2014; **20**: 1121-1129.

- 317 15. de Winter BCM, Mathot RAA, Sombogaard F, Vulto AG, van Gelder T. Nonlinear relationship
318 between mycophenolate mofetil dose and mycophenolic acid exposure: implications for
319 therapeutic drug monitoring. *Clin J Am Soc Nephrol* 2011; **6**: 656-663.
- 320 16. Frymoyer A, Verotta D, Jacobson PA, Long-Boyle J. Population pharmacokinetics of unbound
321 mycophenolic acid in adult allogeneic hematopoietic cell transplantation: effect of
322 pharmacogenetic factors. *Br J Clin Pharmacol* 2013; **75**: 463-475.
- 323 17. Li H, Mager DE, Sandmaier BM, Maloney DG, Bemer MJ, McCune JS. Population
324 pharmacokinetics and dose optimization of mycophenolic acid in HCT recipients receiving oral
325 mycophenolate mofetil. *J Clin Pharmacol* 2013; **53**: 393-402.
- 326 18. Barau C, Furlan V, Debray D, Taburet AM, Barrail-Tran A. Population pharmacokinetics of
327 mycophenolic acid and dose optimization with limited sampling strategy in liver transplant
328 children. *Br J Clin Pharmacol* 2012; **74**: 515-524.
- 329 19. Kim H, Long-Boyle J, Rydholm N, Orchard PJ, Tolar J, Smith AR *et al.* Population
330 pharmacokinetics of unbound mycophenolic acid in pediatric and young adult patients
331 undergoing allogeneic hematopoietic cell transplantation. *J Clin Pharmacol* 2012; **52**:
332 1665-1675.

- 333 20. Wang J, Yang JW, Zeevi A, Webber SA, Girnita DM, Selby R *et al.* IMPDH1 gene
334 polymorphisms and association with acute rejection in renal transplant patients. *Clin Pharmacol*
335 *Ther* 2008; **83**: 711-717.
- 336 21. Sombogaard F, van Schaik RHN, Mathot RA, Budde K, van der Werf M, Vulto AG *et al.*
337 Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated
338 with IMPDH type II 3757T > C polymorphism. *Pharmacogenet Genom* 2009; **19**: 626-634.
- 339 22. Naesens M, Kuypers DR, Verbeke K, Vanrenterghem Y. Multidrug resistance protein 2 genetic
340 polymorphisms influence mycophenolic acid exposure in renal allograft recipients.
341 *Transplantation* 2006; **82**: 1074-1084.
- 342 23. Djebli N, Picard N, Rerolle JP, Le Meur Y, Marquet P. Influence of the UGT2B7 promoter
343 region and exon 2 polymorphisms and comedications on acyl-MPAG production in vitro and in
344 adult renal transplant patients. *Pharmacogenet Genom* 2007; **17**: 321-330.
- 345 24. Kawanishi M, Yano I, Yoshimura K, Yamamoto T, Hashi S, Masuda S *et al.* Sensitive and
346 validated LC-MS/MS methods to evaluate mycophenolic acid pharmacokinetics and
347 pharmacodynamics in hematopoietic stem cell transplant patients. *Biomed Chromatogr* 2015;
348 **29**: 1309-1316.

- 349 25. Savic RM, Jonker DM, Kerbusch T, Karlsson MO. Implementation of a transit compartment
350 model for describing drug absorption in pharmacokinetic studies. *J Pharmacokinet Pharmacodyn*
351 2007; **34**: 711-726.
- 352 26. Jiao Z, Ding JJ, Shen J, Liang HQ, Zhong LJ, Wang Y *et al.* Population pharmacokinetic
353 modelling for enterohepatic circulation of mycophenolic acid in healthy Chinese and the
354 influence of polymorphisms in UGT1A9. *Br J Clin Pharmacol* 2008; **65**: 893-907.
- 355 27. Funaki T. Enterohepatic circulation model for population pharmacokinetic analysis. *J Pharm*
356 *Pharmacol* 1999; **51**: 1143-1148.
- 357 28. Karlsson MO, Sheiner LB. The importance of modeling interoccasion variability in population
358 pharmacokinetic analyses. *J Pharmacokinet Biopharm* 1993; **21**: 735-750.
- 359 29. Yoshimura K, Yano I, Kawanishi M, Nakagawa S, Yonezawa A, Matsubara K.
360 Pharmacokinetics and pharmacodynamics of mycophenolic acid in Nagase albuminemic rats:
361 Evaluation of protein binding effects using the modeling and simulation approach. *Drug Metab*
362 *Pharmacokinet* 2015; **30**: 441-448.

- 363 30. Upton RN, Mould DR. Basic concepts in population modeling, simulation, and model-based
364 drug development: part 3-introduction to pharmacodynamic modeling methods. *CPT*
365 *Pharmacometrics Syst Pharmacol* 2014; **3**: e88.
- 366 31. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive
367 checks for diagnosing nonlinear mixed-effects models. *AAPS J* 2011; **13**: 143-151.
- 368 32. Beal SL. Ways to fit a PK model with some data below the quantification limit. *J Pharmacokinet*
369 *Pharmacodyn* 2001; **28**: 481-504.
- 370 33. Chaudhry HM, Bruce AJ, Wolf RC, Litzow MR, Hogan WJ, Patnaik MS *et al*. The Incidence and
371 Severity of Oral Mucositis among Allogeneic Hematopoietic Stem Cell Transplantation Patients:
372 A Systematic Review. *Biol Blood Marrow Transplant* 2016; **22**: 605-616.
- 373 34. van Hest RM, Doorduijn JK, de Winter BC, Cornelissen JJ, Vulto AG, Oellerich M *et al*.
374 Pharmacokinetics of mycophenolate mofetil in hematopoietic stem cell transplant recipients.
375 *Ther Drug Monit* 2007; **29**: 353-360.
- 376 35. Kemmner S, Verbeek M, Heemann U. Renal dysfunction following bone marrow transplantation.
377 *J Nephrol*. 2017; **30**: 201-209.

36. Sam WJ, Akhlaghi F, Rosenbaum SE. Population pharmacokinetics of mycophenolic acid and its 2 glucuronidated metabolites in kidney transplant recipients. *J Clin Pharmacol* 2009; **49**: 185-195.
37. Nowak I, Shaw LM. Mycophenolic-acid binding to human serum-albumin - characterization and relation to pharmacodynamics. *Clin Chem* 1995; **41**: 1011-1017.
38. Cornell RF, Hari P, Drobyski WR. Engraftment syndrome after autologous stem cell transplantation: an update unifying the definition and management approach. *Biol Blood Marrow Transplant* 2015; **21**: 2061-2068
39. Sahin U, Toprak SK, Atilla PA, Atilla E, Demirer T. An overview of infectious complications after allogeneic hematopoietic stem cell transplantation. *J Infect Chemother* 2016; **22**: 505-514
40. Nagai M, Natsumeda Y, Weber G. Proliferation-linked regulation of type-II IMP dehydrogenase gene in human normal lymphocytes and HL-60 leukemic-cells. *Cancer Res* 1992; **52**: 258-261.
41. Nagai M, Natsumeda Y, Konno Y, Hoffman R, Irino S, Weber G. Selective up-regulation of type-II Inosine 5'-monophosphate dehydrogenase messenger RNA expression in human leukemias. *Cancer Res* 1991; **51**: 3886-3890.

393 42. Uchida N, Wake A, Nakano N, Ishiwata K, Takagi S, Tsuji M *et al.* Mycophenolate and
394 tacrolimus for graft-versus-host disease prophylaxis for elderly after cord blood transplantation:
395 a matched pair comparison with tacrolimus alone. *Transplantation*. 2011; 92: 366-371.
396

Figure legends

Fig. 1 Overview of the basic pharmacokinetic and pharmacodynamic model characterizing mycophenolic acid (MPA), MPA glucuronide (MPAG), MPA acylglucuronide (AcMPAG), and inosine-5'-monophosphate dehydrogenase (IMPDH). GI, gastrointestinal tract; K_a , first-order absorption rate constant; CL_{MPA} , clearance of MPA; CL_{MPAG} , clearance of MPAG; CL_{AcMPAG} , clearance of AcMPAG; V_{MPA} , volume of distribution of MPA; V_{MPAG} , volume of distribution of MPAG; V_{AcMPAG} , volume of distribution of AcMPAG; K_{EHC} , first-order rate constant of enterohepatic circulation; FM_1 , fraction of MPA converted to MPAG.

Fig. 2 Interoccasional pharmacokinetic and pharmacodynamic parameters between one and three weeks after initiation of mycophenolate mofetil (MMF) therapy. (A) The first-order absorption rate constant (K_a); (B) relative bioavailability (F); (C) clearance of MPAG (CL_{MPAG}); (D) clearance of AcMPAG (CL_{AcMPAG}); (E) first-order rate constant for the enterohepatic circulation (K_{EHC}); (F) baseline IMPDH activity (E_0).

Fig. 3 Goodness-of-fit plots of the observed *versus* population predictions (A-D) or individual predictions (E-H) using the final model. (A and E) MPA concentrations; (B and F) MPAG concentrations; (C and G) AcMPAG concentrations; (D and H) IMPDH activity. Each dotted line denotes the line of identity.

Fig. 4 Prediction corrected visual predictive check plots. All open circles represent the observed concentrations or IMPDH activities (prediction corrected). (A-D) one week after initiation of MMF therapy; (E-H) three weeks after initiation of MMF therapy. The solid line represents the median of the observed data. The dotted line represents the observed 5th and 95th percentiles. The shaded area denotes the simulation-based 95% confidence interval for the median or the 5th and 95th percentiles.

Fig. 5 Simulation for the effects of creatinine clearance (CL_{CR}) and diarrhea on the pharmacokinetics and pharmacodynamics of MPA in typical patients based on the final population model. (A) AUC_{0-8} of MPA; (B) AUC_{0-8} of MPAG; (C) AUC_{0-8} of AcMPAG; (D) $AUEC_{0-8}$ of IMPDH activity. The dose of MMF was fixed to 500 mg every 8 h. Each box plot represents the 5th percentile, lower quartile, median, upper quartile, and 95th percentile values obtained from 1000 simulated data sets. *, $p < 0.05$; ***, $p < 0.001$, significantly different from the group with a CL_{CR} of 120 mL/min by the Kruskal-wallis test following

by the Dunn test. †; $p < 0.05$; †††; $p < 0.001$, significantly different from the same CL_{CR} without diarrhea

by the Kruskal-wallis test following by the Dunn test.

Fig. 6 Simulation for the effects of serum albumin (A and B) and C-reactive protein (CRP) (C and D) on the pharmacokinetics and pharmacodynamics of MPA in typical patients based on the final population model. The dose of MMF was fixed to 500 mg every 8 h. (A) AUC_{0-8} of MPA; (B) $AUEC_{0-8}$ of IMPDH activity; (C) the relationship between the MPA plasma concentration and IMPDH activity. The dotted, thin, and thick lines represent 0.1, 1.2, and 10 mg/dL of CRP, respectively. The vertical line represents the MPA concentration of 3.59 $\mu\text{g/mL}$ (the population mean of IC_{50} in the case of CRP 1.2 mg/dL); (D) $AUEC_{0-8}$ of IMPDH activity. Each box plot represents the 5th percentile, lower quartile, median, upper quartile, and 95th percentile values obtained from 1000 simulated data sets. ***, $p < 0.001$, significantly different from the group of 4.2 mg/dL of serum albumin by the Kruskal-wallis test following by the Dunn test. †††; $p < 0.001$, significantly different from the group of 0.1 mg/dL of CRP by the Kruskal-wallis test following by the Dunn test.

Fig. 1





Fig. 2



Observed




Fig. 4




Fig. 5




Fig. 6




Table 1. Characteristics of patients included in the analysis

Characteristics	Number or median (range)	
Gender (male/female)	34/15	
Stem cell source (CBT/BMT/PBT)	34/13/2	
RIC/MAC	23/26	
Body weight (kg)	61.9 (33.5–84.2)	
Age (years)	49 (21–66)	
AST (U/L)	18 (6–206)	
Serum albumin (mg/dL)	3.2 (1.6–4.1)	
Total bilirubin (mg/dL)	0.5 (0.2–2.1)	
Creatinine clearance (mL/min)	112 (20–262)	
C-reactive protein (mg/dL)	1.2 (0–25.1)	
Dose of MMF (mg/day)	1750 (1000–3000)	
Dose normalized by body weight (mg/day/kg)	30.3 (21.3–57.7)	
Diarrhea 1 and 3 weeks after MMF therapy	29/25	
Genetic polymorphisms	Pre-transplant ^a	Post-transplant
(wild/heterozygote/homozygote)		
<i>MRP2</i> -24 C>T (rs717620)	35/12/0	-
<i>UGT2B7</i> -842G>A (rs7439366)	20/21/6	-
<i>IMPDH1</i> -106G>A (rs2278294)	12/23/12	11/23/15
<i>IMPDH1</i> 125G>A (rs2278293)	18/20/9	20/18/11
<i>IMPDH2</i> 3757T>C (rs11706052)	44/2/1	41/8/0

^aGenotypes in two patients were unknown because one patient underwent the second-stem cell transplantation and the other patient was defective in collecting recipient's DNA.

CBT, cord blood transplantation; BMT, bone marrow stem cell transplantation; PBT, peripheral blood stem cell transplantation; RIC, reduced-intensity conditioning; MAC, myeloablative conditioning; AST, aspartate aminotransferase; MMF, mycophenolate mofetil; MRP, multidrug resistance-associated protein; UGT, UDP-glucuronosyltransferase; IMPDH, inosine-5'-monophosphate dehydrogenase

Table 2. Final population pharmacokinetic and pharmacodynamic parameters of MPA

Parameters	Mean	RSE (%)
Pharmacokinetic parameters		
Ka (h^{-1})	1.18	39.5
F	1 FIX	-
$\theta_{\text{CL,MPA}}$ (L/h)	44.5	17.0
$\theta_{\text{V,MPA}}$ (L)	41.5	17.3
$\theta_{\text{CL,MPAG}}$ (L/h)	2.46	14.8
V_{MPAG} (L)	17.3	17.1
$\theta_{\text{K,EHC}}$ (h^{-1})	0.0635	23.8
$\theta_{\text{CL,AcMPAG}}$ (L/h)	3.17	16.7
V_{AcMPAG} (L)	5.50	15.7
Covariates		
Diarrhea on K_{EHC}	0.375	30.7
CL_{CR} on CL_{MPAG}	0.730	69.7
CL_{CR} on $\text{CL}_{\text{AcMPAG}}$	0.537	17.0
ALB on V_{MPA}	-3.71	29.4
ALB on CL_{MPA}	-1.02	43.2
Interindividual variability (IIV; %)		
V_{MPA}	56.9	38.3
F	84.9	6.06
Interoccasional variability (IOV; %)		
Ka	97.9	24.6
F	19.1	47.7
CL_{MPAG}	33.0	22.7
K_{EHC}	91.2	21.9
$\text{CL}_{\text{AcMPAG}}$	42.0	23.8
Residual variability (proportional error; %)		
MPA concentration	40.9	12.4
MPAG concentration	18.8	10.5
AcMPAG concentration	31.4	6.53
Pharmacodynamic parameters		
E_0 ($\mu\text{mol} \cdot \text{h} \cdot \text{sec}^{-1} \cdot \text{mol AMP}^{-1}$)	65.5	10.4

θ_{IC50} ($\mu\text{g/mL}$)	3.59	20.3
Covariates		
CRP on IC_{50}	0.338	47.3
Interindividual variability (IIV, %)		
IC_{50}	81.2	45.3
Interoccasional variability (IOV, %)		
E_0	85.8	27.4
Residual variability (proportional error; %)		
IMPDH activity	46.6	3.73

K_a , first-order absorption rate constant; F , relative bioavailability; CL_{MPA} , clearance of MPA; V_{MPA} , volume of distribution of MPA; CL_{MPAG} , clearance of MPAG; V_{MPAG} , volume of distribution of MPAG; K_{EHC} , first-order rate constant of enterohepatic circulation; CL_{AcMPAG} , clearance of AcMPAG; V_{AcMPAG} , volume of distribution of AcMPAG; CL_{CR} , creatinine clearance; ALB , serum albumin concentration; E_0 , baseline of IMPDH activity; IC_{50} , half-maximal inhibitory concentration; CRP, C-reactive protein.

The final pharmacokinetic and pharmacodynamic models were described as followed: $CL_{MPA} = \theta_{CL,MPA} \times (\frac{ALB}{3.2})^{-1.02}$; $V_{MPA} = \theta_{V,MPA} \times (\frac{ALB}{3.2})^{-3.71}$, $CL_{MPAG} = \theta_{CL,MPAG} \times (\frac{CL_{CR}}{112})^{0.730}$, $K_{EHC} = \theta_{K,EHC} \times (0.375)^{COV}$, $CL_{AcMPAG} = \theta_{CL,AcMPAG} \times (\frac{CL_{CR}}{112})^{0.537}$, and $IC_{50} = \theta_{IC50} \times (\frac{CRP}{1.2})^{0.338}$; COV is set to 0 for patients without diarrhea and 1 for patients with diarrhea.